Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

ody platform with the publication of data in Nature Medicine showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
  • Entered into a five-year contract potentially worth up to $44.4 million with the Department of Defense's Defense Threat Reduction Agency (DTRA), and ramped up activities under this contract to assess bavituximab and other anti-PS antibodies for biodefense applications against viral hemorrhagic fevers.
  • Continued to enroll and dose patients in an ongoing Phase I clinical trial of bavituximab in hepatitis C virus infected patients co-infected with HIV.
  • Was awarded a U.S. patent that includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids, including PS.
  • Reported that the company's anti-PS technology was positively highlighted in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa.
  • Cotara(R) Brain Cancer Program

    • Reported that patient enrollment in the Cotara dosing and dosimetry trial at U.S. brain cancer centers was nearing completion, and that patients in the initial two cohorts of the study have all either met or exceeded the expected median survival time of six months for recurrent glioblastoma multiforme (GBM) patients.
    • Presented data at the Society of Nuclear Medicine 2009 Annual Meeting showing that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. This data confirms a key safety attribute of Cotara - its ability to precisely target tumors. Data showed that the concentration of Cotara in brain tumors was on average more than 300-fold higher than in normal organs.
    • Reported that patient enrollment has exceeded the halfway mark in the Cotara Phase II trial in patients with relapsed GBM.
      '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... ... August 03, 2015 , ... Zeiter’s Septic now performs septic ... owned and operated business, Zeiter’s Septic has been serving the community for over ... installations because of their continued training and perseverance to provide their customers with ...
    (Date:8/3/2015)... UT (PRWEB) , ... August 03, 2015 , ... ... of the T500 cable , a Bluetooth Code Reader accessory that enables a ... iOS products. The T500 helps enable a variety of barcode reading applications with ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay $56.9 million ... which a claimant alleged to have suffered an arterial blood clot including stroke and ... Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In 2009, lawsuits ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Novation, the ... to offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists ... , Annually, more than 8.6 million adverse drug events are reported in the ...
    (Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... from ALS and amputation , AUGUST 3, 2015 – Since winning a South ... March 2015, Not Impossible – an organization whose mission is to develop technology ...
    Breaking Medicine News(10 mins):Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4
    ... have therapeutic benefits , WEDNESDAY, July 22 (HealthDay News) ... in efforts to develop drug treatments for diabetes and ... they found that humanin, which may prevent nerve cells ... blood glucose levels. , "This new role of humanin ...
    ... , INDIANAPOLIS, July 22 Roche Diagnostics ... comprehensive testing solution for rapid cardiac diagnostic needs in point-of-care ... The latest addition to an expanding portfolio of Roche Diagnostics ... immunoassay testing system designed to provide quantitative cardiac marker test ...
    ... , RONKONKOMA, N.Y., July 22 NBTY, Inc. ... marketer of nutritional supplements, today announced it will web cast a conference call ... www.NBTY.com ), on Monday, July 27, 2009 at 9:00 AM (ET). ... at 7:00 AM (ET) that morning. , , ...
    ... , , ... July 22 Decision Resources, one of the world,s leading ... finds that surveyed rheumatologists, perception of Bristol-Myers Squibb,s Orencia is ... the agent when compared to tumor necrosis factor-alpha (TNF-alpha) inhibitors ...
    ... WALTHAM, Mass., July 22 According to ... technology market intelligence, the recent Centers for Medicare and ... are resulting in adoption of antimicrobial-coated access devices, including ... US Markets for Vascular Access Devices 2009 report ...
    ... Dr. Robert Graw announced Nighttime Care Centers opened its seventh urgent ... Center at 882 Muddy Branch Road, Gaithersburg, Maryland 20878. Nighttime Care ... adults when residents do not have access to their regular physicians. ... , "This Care Center will help round ...
    Cached Medicine News:Health News:Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care 2Health News:Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care 3Health News:NBTY to Web Cast Fiscal Third Quarter Conference Call 2Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 2Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 3Health News:Following CMS Cuts to Reimbursement for Medical Errors, New Devices Aimed at Reducing Nosocomial Infections Emerge 2Health News:Following CMS Cuts to Reimbursement for Medical Errors, New Devices Aimed at Reducing Nosocomial Infections Emerge 3Health News:Nighttime Care Centers Announces New Urgent Care Medical Clinic in Montgomery County, Maryland 2
    (Date:8/3/2015)... Texas, Aug. 3, 2015  Luminex Corporation (NASDAQ: ... quarter ended June 30, 2015.  Financial and operating highlights ... Increased second quarter 2015 revenue by 6 percent to ... , Grew second quarter 2015 assay revenue by 22 ... quarter of 2014. , Increased Q2 2015 royalty ...
    (Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
    (Date:8/3/2015)... CHICAGO , August 3, 2015 ... Report 2015 market research with 2020 forecasts as ... the healthcare and medical devices intelligence collection of ... medical simulation market with 2020 forecasts spread across ... supported with 170 tables and figures is now ...
    Breaking Medicine Technology:Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6
    ... 2011 ImpactRx, the pioneer in measuring the ... the rollout of POP 2.0, a proprietary, event-triggered ... physician panels. Triggered by events already ... POP (Point-of-Promotion/Point-of-Prescribing) surveys enable ImpactRx to uniquely capture ...
    ... Ore., June 27, 2011 Bend Research Inc. ( www.bendresearch.com ... named a new president. Jim Nightingale, who ... fourth president in the firm,s 36-year history. ... capacity as Bend Research Chief Executive Officer (CEO) and chairman ...
    Cached Medicine Technology:Enhanced POP 2.0 Provides Custom Insight Into the Physician's Mindset at the Point of Promotion and Prescribing 2Bend Research Inc. Names New President 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: